Interv Akut Kardiol. 2009;8(4):171-174

Statins in the first line of treatment of accute coronary syndrome

Petr Oą»ádal
Kardiologická klinika 2. LF UK a FN Motol, Praha

-

Keywords: -

Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Oą»ádal P. Statins in the first line of treatment of accute coronary syndrome. Interv Akut Kardiol. 2009;8(4):171-174.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344(8934): 1383-1389.
    2. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98(9): 839-844. Go to original source... Go to PubMed...
    3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339(19): 1349-1357.
    4. Ostadal P. Statins in the therapy of acute coronary syndromes. In: Wong BA, editor. Focus in statin research. New York: Nova Publishers; 2006.
    5. Ostadal P, Vojacek J. Statins and acute coronary syndromes. In: Kepper KF, editor. Frontiers in atherosclerosis research. New York: Nova Publishers, 2007.
    6. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. Jama 2001; 285(4): 430-436. Go to original source... Go to PubMed...
    7. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357(9262): 1063-1068. Go to original source... Go to PubMed...
    8. Cannon CP, McCabe CH, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]. J Am Coll Cardiol 2001; 37(suppl A): 334A. Abstract 831-832. Go to original source...
    9. Heeschen C, Hamm CW, Laufs U, Snapinn S, Bohm M, White HD. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105(12): 1446-1452. Go to original source... Go to PubMed...
    10. Schiele R, Gitt AK, Heer T. Early statin use in acute myocardial is associated with a reduced hospital mortality: results of the Mitra-2 [abstract]. Circulation 2000; 102(suppl 2): II-435. Abstract 2117.
    11. Lenderink T, Boersma E, Gitt AK, Zeymer U, Wallentin L, Van de Werf F, et al. Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes. Eur Heart J 2006; 27(15): 1799-1804. Go to original source... Go to PubMed...
    12. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Jama 2001; 285(13): 1711-1718. Go to original source... Go to PubMed...
    13. Liem AH, van Boven AJ, Veeger NJ, Withagen AJ, Robles de Medina RM, Tijssen JG, et al. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J 2002; 23(24): 1931-1937. Go to original source... Go to PubMed...
    14. Arntz HR, Agrawal R, Wunderlich W, Schnitzer L, Stern R, Fischer F, et al. Beneficial effects of pravastatin (+/- colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). Am J Cardiol 2000; 86(12): 1293-1298. Go to original source... Go to PubMed...
    15. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. Jama 2002; 287(24): 3215-3222. Go to original source... Go to PubMed...
    16. Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J 2004; 148(1): e2. Go to original source... Go to PubMed...
    17. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. Jama 2004; 292(11): 1307-1316. Go to original source... Go to PubMed...
    18. LaBlanche JM, Jukema JW, Charbonneau F, Creplet J, Eldar M, Galve E, et al. PRINCESS: Prevention of ischemic events by early treatment of cerivastatin after acute myocardial infarction. In: ESC Congress, 2004; Munich, 2004.
    19. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495-504. Go to original source... Go to PubMed...
    20. Lefer AM, Campbell B, Shin YK, Scalia R, Hayward R, Lefer DJ. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 1999; 100(2): 178-184. Go to original source... Go to PubMed...
    21. Ueda Y, Kitakaze M, Komamura K, Minamino T, Asanuma H, Sato H, et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 1999; 34(7): 2120-2125. Go to original source... Go to PubMed...
    22. Lefer DJ, Scalia R, Jones SP, Sharp BR, Hoffmeyer MR, Farvid AR, et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. Faseb J 2001; 15(8): 1454-1456. Go to original source... Go to PubMed...
    23. Di Napoli P, Antonio Taccardi A, Grilli A, Spina R, Felaco M, Barsotti A, et al. Simvastatin reduces reperfusion injury by modulating nitric oxide synthase expression: an ex vivo study in isolated working rat hearts. Cardiovasc Res 2001; 51(2): 283-293. Go to original source... Go to PubMed...
    24. Bauersachs J, Galuppo P, Fraccarollo D, Christ M, Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme a reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001; 104(9): 982-985. Go to original source... Go to PubMed...
    25. Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002; 105(7): 868-873. Go to original source... Go to PubMed...
    26. Bell RM, Yellon DM. Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003; 41(3): 508-515. Go to original source... Go to PubMed...
    27. Wolfrum S, Dendorfer A, Schutt M, Weidtmann B, Heep A, Tempel K, et al. Simvastatin acutely reduces myocardial reperfusion injury in vivo by activating the phosphatidylinositide 3-kinase/Akt pathway. J Cardiovasc Pharmacol 2004; 44(3): 348-355. Go to original source... Go to PubMed...
    28. Zheng X, Hu SJ. Effects of simvastatin on cardiohemodynamic responses to ischemia-reperfusion in isolated rat hearts. Heart Vessels 2006; 21(2): 116-123. Go to original source... Go to PubMed...
    29. Szarszoi O, Maly J, Ostadal P, Netuka I, Besik J, Kolar F, et al. Effect of acute and chronic simvastatin treatment on postischemic contractile dysfunction in isolated rat heart. Physiol Res 2008; 57(5): 793-796. Go to original source...
    30. Ostadal P, Alan D, Hajek P, Horak D, Vejvoda J, Trefanec J, et al. The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. Mol Cell Biochem 2003; 246(1-2): 45-50. Go to original source... Go to PubMed...
    31. Luo Y, Jiang D, Wen D, Yang J, Li L. Changes in serum interleukin-6 and high-sensitivity C-reactive protein levels in patients with acute coronary syndrome and their response to simvastatin. Heart Vessels 2004; 19(6): 257-262. Go to original source... Go to PubMed...
    32. Macin SM, Perna ER, Farias EF, Franciosi V, Cialzeta JR, Brizuela M, et al. Atorvastatin has an important acute anti-inflammatory effect in patients with acute coronary syndrome: results of a randomized, double-blind, placebo-controlled study. Am Heart J 2005; 149(3): 451-457. Go to original source... Go to PubMed...
    33. Ostadal P, Alan D, Vejvoda J, Cepova J, Kukacka J, Blasko P, et al. Immediate effect of fluvastatin on lipid levels in acute coronary syndrome. Mol Cell Biochem 2007; 306(1-2): 19-23. Go to original source... Go to PubMed...
    34. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol 2008; 51(15): 1440-1445. Go to original source... Go to PubMed...
    35. Michelena HI, Osorio LA, Citkowitz E. Cholesterol levels after 3 days of high-dose simvastatin in patients at moderate to high risk for coronary events. Int J Cardiol 2005; 101(1): 111-114. Go to original source... Go to PubMed...
    36. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000; 36(5): 617-621. Go to original source... Go to PubMed...
    37. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui-Hirai H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001; 104(4): 376-379. Go to original source... Go to PubMed...
    38. Ostadal P, Alan D, Hajek P, Vejvoda J, Mates M, Blasko P, et al. Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial) [ISRCTN81331696]. Curr Control Trials Cardiovasc Med 2005; 6(1): 4. Go to original source... Go to PubMed...
    39. Ostadal P, Alan D, Vejvoda J, Kukacka J, Macek M, Hajek P, et al. Fluvastatin in the Therapy of Acute Coronary Syndrome: Results of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. Arterioscler. Thromb. Vasc. Biol. 2009; 29: e9-e130.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.